Shareholder in Ocular Therapeutix (NASDAQ: OCUL) plans Rule 144 sale of 10,348 shares

Rhea-AI Filing Summary

Ocular Therapeutix shareholder files notice to sell shares under SEC Rule 144. The filing covers up to 10,348 shares of common stock, with an aggregate market value of $93,560.41, to be sold through Morgan Stanley Smith Barney on NASDAQ.

The shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. The notice also reports a prior sale over the last three months of 1,878 common shares for gross proceeds of $22,616.19.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10348	93560.41	217691779	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/11/2026	Restricted stock vesting under a registered plan	Issuer			10348	02/11/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SANJAY NAYAK 15 Crosby Drive Bedford MA 01730	Common	11/24/2025	1878	22616.19

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the OCUL Rule 144 filing disclose about planned share sales?

The filing discloses a planned sale of up to 10,348 OCUL common shares under Rule 144. These shares have an aggregate market value of $93,560.41 and are expected to be sold on NASDAQ through Morgan Stanley Smith Barney.

How were the OCUL shares in this Rule 144 notice acquired?

The OCUL shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. The amount acquired was 10,348 common shares, matching the number covered by the planned Rule 144 sale in the notice.

What recent OCUL share sales are reported for the same shareholder?

The notice reports that 1,878 OCUL common shares were sold on November 24, 2025 for gross proceeds of $22,616.19. This transaction is disclosed as part of the required three-month sale history under Rule 144.

How many OCUL shares are outstanding compared with the planned Rule 144 sale?

The filing states that 217,691,779 OCUL common shares are outstanding. The planned Rule 144 sale covers 10,348 shares, which is a small portion of the total shares outstanding disclosed in the notice.

Which broker and exchange are involved in the OCUL Rule 144 share sale?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker handling the sale. The common shares covered by the notice are expected to be sold on the NASDAQ stock market, according to the disclosure.

What representation does the selling OCUL shareholder make in the Rule 144 notice?

The shareholder represents that they do not know any material adverse, non-public information about Ocular Therapeutix’s current or prospective operations. This representation is made by signing the notice, as required for sales relying on Rule 144.